soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm SOUL: Oral Semaglutide Bests Usual Care in SOUL trial shows oral semaglutide

Cardiovascular outcome trials (including LEADER, SUSTAIN-6, REWIND, and SELECT) have demonstrated that certain GLP-1 receptor agonists reduce major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors

If you require emergency surgery, inform your attending physician, anesthesiologist, and surgeon about your medication as soon as possible

Gradual, Natural-Looking Results: The fat dissolves over time, creating a natural contour

Having sufficient knowledge of the GSH system and the regulation and functions of GPx is essential to prevent metabolic alterations and to develop effective strategies for treating these diseases

One option you may have heard about is Wegovy , a treatment designed to support long-term weight management